Eli Lilly Stocks Move Lower With Higher Target Facing a Volume-Price Tradeoff

What happened

Cantor Fitzgerald raised its Eli Lilly price target to $1,600 from $1,440 and maintained an Overweight rating. The article reports quarterly revenue of $24.397 billion; Mounjaro and Zepbound supplied 65.9% of it, while worldwide volume rose 53% and realized prices fell 15%.

Confirmed

Global impact / market context

Mounjaro and Zepbound are driving growth, but their large share of revenue also concentrates Lilly’s business in these medicines. If lower realized prices outpace gains from higher sales volumes, revenue and earnings growth could weaken, making the company’s ability to sustain profit per sale important to its outlook.

Analyst inference

The article highlights a tension for Lilly: increasing medicine sales volumes can support revenue, but lower realized prices mean the company collects less per sale. Because Mounjaro and Zepbound account for much of quarterly revenue, this balance could influence earnings and investor expectations.

Analyst inference

What to watch

1. Watch future sales and revenue updates for Mounjaro and Zepbound, which together generated 65.9% of quarterly revenue, to assess whether their growth continues. Analyst inference
2. Compare reported volume growth with realized prices, meaning the amounts Lilly actually collects per sale; the article reports volume up and prices down. Analyst inference
3. Assess whether Lilly’s product sales can sustain revenue growth as realized prices decline, since the article identifies that balance as a key operating test. Analyst inference

Evidence

• gurufocus.com